Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "2026年1月5日至2026年1月7日300750股价走势分析"

Looking for quality documents?
store icon
Biotech CE Dialysis Tubing – Repligen
Economy packaging provides a 10-meter supply of a particular CE tubing MWCO & flatwidth to meet the demands of ongoing & frequent dialysis applications. Product Specifications: Properties: Hydrophilic, symmetric porosity 9 MWCOs: 100-500 D, 500-1000 D, 3.5-5 kD, 8-10 kD, 20 kD, 50 kD, 100 kD, 300 kD & 1000 kD 4 Flat Widths: 10 mm, 16 mm, 24 mm & 31 mm Qty & Pkg: 10 meter/roll, wet in 0.05% sodium azide
store icon
Biotech CE Dialysis Tubing – Repligen
Economy packaging provides a 10-meter supply of a particular CE tubing MWCO & flatwidth to meet the demands of ongoing & frequent dialysis applications. Product Specifications: Properties: Hydrophilic, symmetric porosity 9 MWCOs: 100-500 D, 500-1000 D, 3.5-5 kD, 8-10 kD, 20 kD, 50 kD, 100 kD, 300 kD & 1000 kD 4 Flat Widths: 10 mm, 16 mm, 24 mm & 31 mm Qty & Pkg: 10 meter/roll, wet in 0.05% sodium azide
store icon
KONDUiT Base Unit – Repligen
KONDUiT Base Unit: Conducivity, UV and Temperature Integrated Monitor for use with KR2i and KMPi Automated TFF Process Control for user-set conductivity limit in KF Comm Automated TFF Process Control for user-set Absorbance in KF Comm (with purchase of UV Photometer) 2 Conductivity Inputs -2 Temperature Inputs 1 UV Pho
publications icon
Continuous Manufacturing: A Changing Processing Paradigm Publication
Although continuous manufacturing is well established for bulk chemicals, complex automation and validation challenges limit continuous applications for biologics manufacturing. While only a few approved biologic products in the market-less than 10%, according to estimates by Eric Langer, managing partner, BioPlan Associates-are manufactured through perfusion or continuous downstream processing, the field is evolving (1). Most of these processes are done piecewise, however, and are not truly continuous. 
external link icon
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., May 25, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at two upcoming investor conferences. William Blair 41 st Annual Growth Stock conference being held June 1 - 3.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, June 1, at 1:40 p.m. EST.   Jefferies Virtual Healthcare Conference being held June 1 - 3.   Tony J. Hunt, President and Chief Executive Officer and Jon K. Snodgres, Chief Financial Officer, will participate in a fireside chat on Thursday, June 3, at 2:30 p.m. EST. A live webcast of the discussions will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences
external link icon
Repligen Corporation to Present at William Blair Growth Conference
WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45 th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3 rd at 1:20 p.m. CT. A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug
external link icon
Repligen Receives First Milestone Payment From Pfizer Under Licensing Agreement for Spinal Muscular Atrophy Program
WALTHAM, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has received a $1 million milestone payment from Pfizer, Inc. under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement") for the development of compounds to treat spinal muscular atrophy (SMA). This first milestone payment was triggered by completion of specific program activities and coincides with the successful completion of all transition obligations by Repligen. Repligen announced the Agreement in January of this year, at which time it received an upfront payment of $5 million. Repligen remains eligible to receive up to $64 million in additional success-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement. "Consistent with our strategic decision last August to focus on building Repligen's bioprocessing business while scaling back our investment in therapeutics, we out-licensed the SMA
external link icon
Repligen Receives Milestone Payment From Pfizer
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that on December 30, 2014, it received a $1 million milestone payment from Pfizer, Inc. under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement") for the development of compounds to potentially treat spinal muscular atrophy (SMA), a neuromuscular disease that typically presents in children under age two. Since announcing the Agreement in January 2013, Repligen has received $7 million in upfront and milestone payments. Repligen remains eligible to receive up to $63 million in additional performance-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement. 2014 Revenue Repligen also today reported preliminary, unaudited total revenue of $63-$63.5 million for the fiscal year ended December 31, 2014. This total revenue figure is comprised of approximately $3 million in revenue from out-licensed therapeutic
external link icon
Repligen Completes Expansion of U.S. Manufacturing Facility
WALTHAM, Mass., Nov. 1, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced it has completed a 9,000 square foot expansion of its manufacturing facilities at its Waltham headquarters to meet growth in demand for its bioprocessing products and to ensure that the quality, capacity and support needs of its customers continue to be met. A dedicated production suite more than doubles capacity for the Company's OPUS ® line of pre-packed chromatography columns, with cleanrooms built to ISO 7 specifications providing an appropriately controlled environment to satisfy the Good Manufacturing Practices (GMP) standards of the Company's biopharmaceutical customers. "This expansion will enable us to meet the critical needs of our customers for quality and timely delivery," said Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen. "The new cleanroom suite enables us to produce OPUS ® columns under the highest quality standard demanded by